Publicação
Mapping the Scientific Landscape of GLP-1 and Dual GLP-1/GIP Receptor Agonists in Obesity Treatment
| Resumo: | This thesis investigates the evolution of scientific literature on GLP-1 and dual GLP-1/GIP receptor agonists for obesity treatment between 2010 and 2024. Using data retrieved from OpenAlex and processed in R, the study applies scientometric techniques and sentiment analysis to assess publication trends, institutional and geographic contributions, and the influence of industry-affiliated research. A comparative sentiment analysis was performed on industry versus non-industry publications, revealing notable tonal discrepancies, particularly for Tirzepatide, where early literature was more positive in industry-sponsored studies. Additionally, author-level metrics such as publication counts, citations, and h-indexes were used to evaluate individual contributions to the field. Results highlight a research landscape dominated by the United States and Denmark, reflecting the influence of pharmaceutical leaders Eli Lilly and Novo Nordisk. The findings underscore the dual role of scientific publishing as both a vehicle for evidence generation and a strategic tool for shaping drug narratives. Limitations include the exclusion of studies due to missing metadata and the short observation window for newly approved therapies. Future research should update the analysis as more longitudinal and real-world data become available, particularly to assess long-term safety, efficacy, and scientific discourse evolution. |
|---|---|
| Autores principais: | Santos, Beatriz Rodrigues dos |
| Assunto: | Liraglutide Semaglutide Tirzepatide Obesity GLP-1 Scientometrics SDG 3 - Good health and well-being SDG 9 - Industry, innovation and infrastructure SDG 17 - Partnerships for the goals |
| Ano: | 2025 |
| País: | Portugal |
| Tipo de documento: | dissertação de mestrado |
| Tipo de acesso: | acesso aberto |
| Instituição associada: | Universidade Nova de Lisboa |
| Idioma: | inglês |
| Origem: | Repositório Institucional da UNL |
| Resumo: | This thesis investigates the evolution of scientific literature on GLP-1 and dual GLP-1/GIP receptor agonists for obesity treatment between 2010 and 2024. Using data retrieved from OpenAlex and processed in R, the study applies scientometric techniques and sentiment analysis to assess publication trends, institutional and geographic contributions, and the influence of industry-affiliated research. A comparative sentiment analysis was performed on industry versus non-industry publications, revealing notable tonal discrepancies, particularly for Tirzepatide, where early literature was more positive in industry-sponsored studies. Additionally, author-level metrics such as publication counts, citations, and h-indexes were used to evaluate individual contributions to the field. Results highlight a research landscape dominated by the United States and Denmark, reflecting the influence of pharmaceutical leaders Eli Lilly and Novo Nordisk. The findings underscore the dual role of scientific publishing as both a vehicle for evidence generation and a strategic tool for shaping drug narratives. Limitations include the exclusion of studies due to missing metadata and the short observation window for newly approved therapies. Future research should update the analysis as more longitudinal and real-world data become available, particularly to assess long-term safety, efficacy, and scientific discourse evolution. |
|---|